Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +55

B. Metzler seel. Sohn & Co. AG Lowers Position in Edwards Lifesciences Corporation $EW - MarketBeat

AI-generated analysis

πŸ“ˆ Edwards Lifesciences reported quarterly EPS of $0.78 and revenue of $1.74 billion, beating analyst estimates.

πŸ“‰ B. Metzler seel. Sohn & Co. AG lowered its position by 25.5% in Q2, selling 14,264 shares.

πŸ“ˆ Multiple institutional investors including Rehmann Capital and Covestor Ltd increased their EW stakes in Q4.

πŸ’° The company maintains a strong balance sheet with a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

🎯 Analysts maintain a 'Moderate Buy' consensus with an average price target of $100.27.

πŸ“Š Revenue grew 13.6% year over year, demonstrating solid top-line growth for the medical device firm.

Bullish Signals
  • Edwards Lifesciences reported quarterly EPS of $0.78 and revenue of $1.74 billion, both exceeding analyst estimates.
  • The company achieved a 13.6% year-over-year revenue increase, demonstrating strong business growth.
  • Institutional investors such as Rehmann Capital Advisory Group and Covestor Ltd increased their holdings in Q4.
  • Analyst consensus remains 'Moderate Buy' with an average price target of $100.27, indicating confidence in future performance.
Risk Factors
  • B. Metzler seel. Sohn & Co. AG reduced its stake by 25.5% in the second quarter, selling 14,264 shares.
  • Corporate insiders sold a total of 5,045 shares valued at $457,749 in the last ninety days.
Full Analysis
Edwards Lifesciences Corporation (NYSE: EW) reported stronger-than-expected quarterly results, posting $0.78 in earnings per share and $1.74 billion in revenue, representing a 13.6% year-over-year increase. The company's stock opened at $90.00, trading near the middle of its 12-month range, with analysts maintaining a 'Moderate Buy' consensus and an average price target of $100.27. Institutional ownership dynamics shifted in the second quarter as B. Metzler seel. Sohn & Co. AG reduced its stake by 25.5%, selling 14,264 shares while retaining a position valued at approximately $3.78 million. Conversely, several other institutional investors increased their holdings during the fourth quarter, including Rehmann Capital Advisory Group, Quadrant Capital Group LLC, and Covestor Ltd, signaling continued institutional interest despite the reduction by Metzler. Analyst sentiment remains robust with 17 Buy ratings against six Holds from major firms like UBS Group, Royal Bank of Canada, and TD Cowen. The company maintains a strong balance sheet with a current ratio of 4.52 and minimal debt, while insiders have sold a total of 5,045 shares in the last ninety days under pre-arranged trading plans.